Dr. Schreiber is the Morris Loeb Research Professor at Harvard University, Founding Core Member of the Broad Institute, Emeritus, and a member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. His research has been recognized through numerous awards, including the Wolf Prize in Chemistry.

His research integrates chemical biology and human biology to advance the discovery of novel therapeutics. His lab discovered the first molecular glues and developed the first bifunctional compounds that recruit neosubstrates to enzymes in cells. He co-discovered mTOR and illuminated the nutrient-response signaling network, discovered the first histone deacetylase (HDAC) and the role of chromatin marks in gene expression, and, with Gerry Crabtree, mapped the first membrane to nuclease signaling pathway (calcium–calcineurin–NFAT).

His development of diversity-oriented synthesis has led to the discovery of many promising agents, including a novel mechanism-of-action anti-malarial agent now in human clinical trials. His most recent discovery revealed a novel cell state responsible for the ability of cancers to resist a wide range of therapies, and a means to target the cancer-therapy-resistant state.

Dr. Schreiber extended chemical biology principles to medicine by participating in the founding of 14 biotech companies, beginning with Vertex Pharmaceuticals, whose efforts have made cystic fibrosis a manageable disease. These companies or Schreiber’s lab have developed 18 novel in-human therapeutic agents that are being tested in human clinical trials or used as FDA-approved drugs.